ATE443131T1 - Hemmung des apoptoseprozesses und verbesserung der zelleistung - Google Patents

Hemmung des apoptoseprozesses und verbesserung der zelleistung

Info

Publication number
ATE443131T1
ATE443131T1 AT02742400T AT02742400T ATE443131T1 AT E443131 T1 ATE443131 T1 AT E443131T1 AT 02742400 T AT02742400 T AT 02742400T AT 02742400 T AT02742400 T AT 02742400T AT E443131 T1 ATE443131 T1 AT E443131T1
Authority
AT
Austria
Prior art keywords
cell
inhibition
improvement
cell performance
related product
Prior art date
Application number
AT02742400T
Other languages
English (en)
Inventor
Mitchell Reff
Michael Betenbaugh
Bruno Figueroa
Eric Ailor
Marie Hardwick
Original Assignee
Biogen Idec Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Univ Johns Hopkins filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE443131T1 publication Critical patent/ATE443131T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02742400T 2001-07-10 2002-07-10 Hemmung des apoptoseprozesses und verbesserung der zelleistung ATE443131T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30381301P 2001-07-10 2001-07-10
PCT/US2002/021606 WO2003006607A2 (en) 2001-07-10 2002-07-10 Inhibition of apoptosis process and improvement of cell performance

Publications (1)

Publication Number Publication Date
ATE443131T1 true ATE443131T1 (de) 2009-10-15

Family

ID=23173824

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02742400T ATE443131T1 (de) 2001-07-10 2002-07-10 Hemmung des apoptoseprozesses und verbesserung der zelleistung

Country Status (13)

Country Link
US (1) US7604989B2 (de)
EP (1) EP1414948B1 (de)
JP (2) JP4435563B2 (de)
KR (1) KR20040044433A (de)
CN (1) CN1526011A (de)
AT (1) ATE443131T1 (de)
AU (1) AU2002315534B2 (de)
CA (1) CA2452005C (de)
DE (1) DE60233738D1 (de)
MX (1) MXPA04000281A (de)
NO (1) NO20040101L (de)
WO (1) WO2003006607A2 (de)
ZA (2) ZA200508985B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
KR100454016B1 (ko) * 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
ES2345335T3 (es) 2003-02-01 2010-09-21 Millipore Corporation Elementos geneticos mejorados que proporcionan altos niveles de expresion.
EP1676911B1 (de) * 2003-10-24 2010-04-21 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Neue rekombinante tierzellen mit hoher proteinproduktion, verfahren zur konstruktion davon sowie verfahren zur massenproduktion von protein unter verwendung davon
ATE546531T1 (de) * 2003-12-31 2012-03-15 Kalobios Inc Transaktivierungssystem für säugerzellen
WO2007015691A2 (en) * 2004-07-23 2007-02-08 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
AU2005333513B2 (en) * 2004-07-23 2011-06-02 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
GB0509965D0 (en) 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
EP2011880B1 (de) * 2006-04-13 2012-10-24 Chugai Seiyaku Kabushiki Kaisha Taurintransporter-gen
JP2009535019A (ja) * 2006-04-21 2009-10-01 バイエル・ヘルスケア・エルエルシー 灌流培養への哺乳動物細胞中の抗アポトーシス遺伝子の応用
EP2118270A2 (de) * 2007-01-08 2009-11-18 Millipore Corporation Zellkulturverfahren für die produktion rekombinanter proteine bei verminderter konzentration von einem oder mehreren kontaminanten
EP2300600B1 (de) * 2008-06-13 2015-09-30 Janssen Biotech, Inc. Verfahren zur verbesserung von lebensfähigkeit und produktivität bei der zellkultur
US20130065312A1 (en) * 2009-11-03 2013-03-14 The Johns Hopkins University Method and composition for generating programmed cell death resistant algal cells
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
KR102711314B1 (ko) 2018-06-28 2024-09-27 삼성디스플레이 주식회사 유기 발광 표시 장치

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DE669986T1 (de) * 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US5897992A (en) * 1996-09-27 1999-04-27 Cold Spring Harbor Laboratory Cell-free assay using oncogene-induced apoptosis in drug-resistant cells
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
WO2000008057A2 (en) * 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
US6570002B1 (en) * 1999-02-26 2003-05-27 The Johns Hopkins University Inhibitor of programmed cell death
US6140118A (en) * 1999-08-11 2000-10-31 Wisconsin Alumni Research Foundation Avian blastodermal cell lines
CA2384880C (en) * 1999-09-27 2010-09-21 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
NZ518718A (en) * 1999-11-12 2004-03-26 Merck & Co Inc Diaryl piperidyl pyrrole derivatives as antiprotozoal agents, treatment or prophylaxis of coccidiosis
KR100454016B1 (ko) 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
EP1348758A1 (de) 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Wirtszellen mit verbessertem Überleben und Verfahren zur Herstellung von diesen Zellen

Also Published As

Publication number Publication date
ZA200400137B (en) 2006-06-28
EP1414948B1 (de) 2009-09-16
WO2003006607A9 (en) 2003-04-10
WO2003006607A3 (en) 2003-07-31
MXPA04000281A (es) 2004-07-23
EP1414948A4 (de) 2006-06-21
ZA200508985B (en) 2006-07-26
WO2003006607A2 (en) 2003-01-23
DE60233738D1 (de) 2009-10-29
EP1414948A2 (de) 2004-05-06
KR20040044433A (ko) 2004-05-28
CN1526011A (zh) 2004-09-01
JP4435563B2 (ja) 2010-03-17
CA2452005C (en) 2011-03-15
NO20040101L (no) 2004-03-09
US20030064510A1 (en) 2003-04-03
AU2002315534B2 (en) 2008-05-22
JP2009118851A (ja) 2009-06-04
US7604989B2 (en) 2009-10-20
CA2452005A1 (en) 2003-01-23
JP2005525782A (ja) 2005-09-02

Similar Documents

Publication Publication Date Title
ATE443131T1 (de) Hemmung des apoptoseprozesses und verbesserung der zelleistung
EP1444329A4 (de) Sich in schlagende kardiomyozyten verwandelnde stammzellen
NO20065512L (no) O-bundne gykoformer av polypeptider og fremgangsmater for deres fremstilling.
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
TW200501976A (en) Compositions containing peptide copper complexes and metalloproteinase inhibitors, and methods related thereto
AU8490901A (en) Urea compounds and methods of uses
ATE319465T1 (de) Therapeutische verwendung von extrakten aus sophora flavescens oder sophora subprostrata
SG170082A1 (en) Methods for regulating inflammatory mediators and peptides useful therein
MXPA02004666A (es) Gelatinas recombinantes.
CY1105772T1 (el) Συνθεσεις και μεθοδοι για βελτιωμενη κυτταρικη καλλιεργεια
DE69721329D1 (de) Zusammensetzung zur Verzögerung des Haarwuchses und entsprechende Verwendung
MX9708217A (es) Fragmentos de angiostatina y angiostatina agregada y metodos de uso.
MXPA03002778A (es) Polipeptidos antiangiogenicos y metodos para inhibir angiogenesis.
PL372303A1 (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
IL124015A0 (en) Pharmaceutical compositions comprising a protein
ES2164653T3 (es) Procedimiento para producir heterociclos polihidroxilicos que contienen nitrogeno n-sustituidos.
CO5040059A1 (es) Composiciones para el control de insectos y/o miembros del orden acarina que comprende una mezcla de emamectina a y lufenuron
TW200740999A (en) Therapeutic reprogramming of germ-line stem cells
PL1976393T3 (pl) Zawiesina spożywcza zawierająca beta-glukan i sposób jej wytwarzania
WO2003066814A3 (en) Peptide-dependent upregulation of telomerase expression
PL374504A1 (en) 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
EA200300572A1 (ru) Комбинированная терапия эстроген-зависимых заболеваний
WO2003082900A3 (en) Self-assembling-peptide-based structures and processes for controlling the self-assembly of such structures
MXPA02007787A (es) Moleculas trade y uso relacionado con las mismas.
ATE408692T1 (de) Kälteinduzierter expressionsvektor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties